Chief Technology Officer
Vivodyne, Inc.
Philadelphia, Pennsylvania
Anthony Bahinski, Ph.D., MBA, FAHA, is Chief Technology Officer at Vivodyne, where he leads the translation of Vivodyne’s automated platform for massively scalable safety and efficacy testing on lifelike lab-grown human tissues to pharmaceutical and regulatory partners. Prior to joining Vivodyne, he served as the Global Head of Safety Pharmacology at GlaxoSmithKline. Dr. Bahinski’s career spans academic research and large Pharma, with more than 25 years’ experience in the pharmaceutical industry. He served on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA, and FDA collaborative efforts in development of organ chip systems. Dr. Bahinski has served on several advisory boards and is currently member of the Science Board of the US FDA, and formerly of the US EPA Board of Scientific Counselors (BOSC), Industrial Advisory Board for Dutch Research Council awarded SMART Organ on Chip (OoC) project and European ORgan-on-Chip In Development (ORCHID) Advisory Board. He is a member of the Editorial Board of the journals Applied In Vitro Toxicology and Frontiers in Pharmacology of Ion Channels and Channelopathies. He has served on Peer Review Panels at the NIH, US EPA, and NCI SBIR. Dr. Bahinski is author/co-author of over 45 publications including peer-reviewed articles and book chapters.
Wednesday, October 25, 2023
1:30 PM – 2:30 PM ET